Denali Therapeutics (DNLI) Equity Ratio: 2017-2025
Historic Equity Ratio for Denali Therapeutics (DNLI) over the last 8 years, with Sep 2025 value amounting to 0.88.
- Denali Therapeutics' Equity Ratio fell 3.24% to 0.88 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.88, marking a year-over-year decrease of 3.24%. This contributed to the annual value of 0.89 for FY2024, which is 0.16% up from last year.
- Per Denali Therapeutics' latest filing, its Equity Ratio stood at 0.88 for Q3 2025, which was down 0.37% from 0.88 recorded in Q2 2025.
- In the past 5 years, Denali Therapeutics' Equity Ratio ranged from a high of 0.92 in Q2 2024 and a low of 0.66 during Q3 2022.
- In the last 3 years, Denali Therapeutics' Equity Ratio had a median value of 0.89 in 2024 and averaged 0.88.
- As far as peak fluctuations go, Denali Therapeutics' Equity Ratio fell by 15.33% in 2021, and later soared by 36.82% in 2023.
- Over the past 5 years, Denali Therapeutics' Equity Ratio (Quarterly) stood at 0.69 in 2021, then climbed by 4.17% to 0.71 in 2022, then increased by 25.15% to 0.89 in 2023, then grew by 0.16% to 0.89 in 2024, then decreased by 3.24% to 0.88 in 2025.
- Its Equity Ratio stands at 0.88 for Q3 2025, versus 0.88 for Q2 2025 and 0.88 for Q1 2025.